Updated:
PathoCapital
PathoCapital is a privately owned investment company that focuses on healthcare investments. It has made 7 investments, including a Series B investment in...
PathoCapital
PathoCapital is a privately owned investment company that focuses on healthcare investments. It has made 7 investments, including a Series B investment in Aptinyx on December 18, 2017. PathoCapital has also facilitated 3 portfolio exits, with ReliefBand Technologies being its most recent exit on October 17, 2022.
General information
Firm type
Private Equity
Year founded
2009
Location
Region
North America
Country
United States
City
Northbrook
Corporate office
Northbrook, IL, United States
Sector focus
Frequently asked questions
How does PathoCapital source deals?
The firm uses a proprietary direct-outreach model targeting managing partners of independent pathology groups. Rather than participating in broad auction processes run by investment banks, PathoCapital identifies regional laboratories facing succession challenges or capital-expenditure needs for digital pathology transitions, and negotiates bilateral transactions.
Is PathoCapital structured as a private equity firm or a strategic healthcare operator?
PathoCapital functions as a hybrid: a financial sponsor that takes control positions but derives its post-acquisition value-creation plan almost entirely from operational expertise in lab management, CLIA compliance, and payer credentialing. The firm does not rely on high leverage or multiple arbitrage alone, distinguishing it from generalist lower-middle-market buyout funds.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: